-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Tesamorelin 5mg is a synthetic research peptide studied in relation to growth hormone-releasing hormone pathway research, growth hormone axis signalling, IGF-1 pathway models, metabolic research and visceral adipose tissue research contexts.
Tesamorelin is commonly described as a synthetic analogue of human growth hormone-releasing hormone, also known as GHRH or growth hormone-releasing factor. PubChem lists tesamorelin with the molecular formula C221H366N72O67S and identifies it under names including Tesamorelin and TH9507.
This product is supplied for laboratory research use only. It is not a medicine, supplement, fat loss product, metabolic treatment, anti-ageing product, body composition product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Tesamorelin |
| Common research names | Tesamorelin acetate, TH9507, GHRH analogue |
| Size | 5mg |
| Product type | Research peptide |
| Research category | Metabolic Research / Growth Hormone Research |
| Common research interest | GHRH signalling, GH axis research, IGF-1 pathway studies, metabolic pathway research |
| Peptide type | Synthetic growth hormone-releasing hormone analogue |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, fat loss or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Tesamorelin | Synthetic GHRH analogue | Studied in relation to growth hormone-releasing hormone receptor signalling |
| GHRH 1-44 analogue structure | Modified growth hormone-releasing hormone sequence | Studied for GH axis and IGF-1 pathway research |
| N-terminal modification | Stabilising peptide modification | Commonly discussed in relation to improved resistance to enzymatic degradation |
| Molecular formula | C221H366N72O67S | Listed in PubChem for tesamorelin |
| Molecular weight | Approximately 5136 g/mol | Useful for laboratory concentration and molar calculation planning |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
Tesamorelin is listed by PubChem with the molecular formula C221H366N72O67S. Product identity, salt form, purity and batch information should always be confirmed through supplier documentation and the Certificate of Analysis.
Tesamorelin is studied as a growth hormone-releasing hormone analogue. In research models, GHRH-related compounds are examined for how they interact with the growth hormone-releasing hormone receptor and influence downstream growth hormone and IGF-1 signalling.
In clinical research settings, tesamorelin has been investigated for its relationship with visceral adipose tissue, cardiometabolic markers and growth hormone axis signalling. A PubMed-indexed review describes tesamorelin as effective for improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26 to 52 weeks, while noting limitations including cost and lack of long-term safety and adherence data.
This should be understood as research literature context only. It should not be used as a claim that a research-use Tesamorelin 5mg vial is approved, safe or effective for human fat loss, body composition, anti-ageing or metabolic treatment.
| Research Area | Tesamorelin |
| Main research category | GHRH analogue research |
| Parent pathway context | Growth hormone-releasing hormone pathway |
| Common receptor interest | GHRH receptor signalling |
| Downstream research interest | GH and IGF-1 pathway models |
| Metabolic research interest | Visceral adipose tissue and metabolic signalling research |
| Clinical research context | Studied in HIV-associated lipodystrophy and visceral adiposity settings |
| Evidence limitation | Clinical research context does not make research vials approved for human use |
| Product limitation | Research use only, not approved for human use |
| Feature | Tesamorelin | CJC-1295 |
| Research class | GHRH analogue | Modified GHRH analogue |
| Main pathway | GHRH receptor pathway | GHRH receptor pathway |
| Common research interest | GH axis, IGF-1 and metabolic research | GH secretagogue and extended GHRH pathway research |
| Structure discussion | GHRH 1-44 analogue with stabilising modification | May be discussed with or without DAC depending on product type |
| Clinical medicine context | Regulated tesamorelin medicines exist overseas for specific indications | Research peptide context varies by product |
| Human-use claim | Not appropriate for this research product | Not appropriate for research products |
| Feature | Tesamorelin | AOD-9604 |
| Research class | GHRH analogue | hGH fragment research peptide |
| Parent pathway | Growth hormone-releasing hormone pathway | Human growth hormone fragment pathway |
| Main research interest | GH release pathway, IGF-1 signalling and metabolic research | Lipolysis pathway and adipocyte research |
| Full GH replacement | No | No |
| Common SEO risk | Being marketed as a fat loss or anti-ageing peptide | Being marketed as a fat loss peptide |
| Safer positioning | GHRH analogue research peptide | hGH fragment research peptide |
| Strength | Product Page Positioning |
| Tesamorelin 5mg | Lower-strength research vial for protocol-specific concentration planning |
| Tesamorelin 10mg | Standard research vial for GHRH analogue research |
| Tesamorelin 20mg | Higher-strength research vial for laboratory concentration planning |
Tesamorelin strengths should be treated as product variants, not duplicate product pages. If multiple strengths are listed separately, each page should have a strength-specific title, meta description, slug, concentration table and internal links to reduce SEO cannibalisation.
| Common Online Claim | Safer Research-Use Wording |
| Fat loss | Studied in relation to visceral adipose tissue and metabolic pathway research |
| Visceral fat reduction | Studied in controlled clinical research contexts, not an approved claim for research vials |
| Anti-ageing | Not an approved or appropriate product claim |
| Growth hormone boost | Better framed as GHRH receptor and GH axis signalling research |
| IGF-1 support | Studied in relation to downstream IGF-1 pathway models |
| Body recomposition | Not an approved or appropriate product claim |
| Metabolic treatment | Not an approved or appropriate product claim |
| HIV lipodystrophy treatment | Only relevant to approved regulated medicines, not research-use vials |
Tesamorelin 5mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for fat loss, visceral fat reduction, obesity treatment, HIV-associated lipodystrophy treatment, anti-ageing, body transformation, bodybuilding, metabolic health, recovery, performance enhancement or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Tesamorelin 5mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 5mg Vial | Final Concentration |
| 0.5mL | 10mg/mL |
| 1mL | 5mg/mL |
| 2mL | 2.5mg/mL |
| 2.5mL | 2mg/mL |
| 5mL | 1mg/mL |
| 10mL | 0.5mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Tesamorelin 5mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Tesamorelin peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Tesamorelin 5mg is not supplied for human or animal administration. It is a laboratory research-use product only.
Regulated tesamorelin medicines have product-specific prescribing information and formulation-specific administration instructions. Those instructions are not transferable to research-use peptide vials, different strengths, different suppliers or non-approved products.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
| Strength check | Confirmation that the 5mg vial strength matches the approved research protocol |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
Because tesamorelin is commonly discussed online in relation to fat loss, visceral fat and anti-ageing, product pages should avoid wording that could be interpreted as encouraging human fat loss, self-injection, body transformation or treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Clearly separate research vials from regulated medicines | Avoids unsafe and misleading comparisons |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a fat loss product | Creates human-use and compliance risk |
| Never make visceral fat reduction claims for research vials | Not an approved or appropriate claim for this product |
| Never market it as HIV lipodystrophy treatment | Only regulated medicines can make approved treatment claims |
| Never make anti-ageing claims | Not an approved or appropriate product claim |
| Never compare it directly to approved medicines as if equivalent | Misleading and clinically inappropriate |
| Never copy dosing from EGRIFTA or other regulated medicine labels | Formulations, strengths and approved contexts differ |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 5mg | 0.5mL | 10mg/mL |
| 5mg | 1mL | 5mg/mL |
| 5mg | 2mL | 2.5mg/mL |
| 5mg | 2.5mL | 2mg/mL |
| 5mg | 5mL | 1mg/mL |
| 5mg | 10mL | 0.5mg/mL |
If a researcher adds 1mL of suitable research-grade diluent to a 5mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Tesamorelin is a synthetic research peptide commonly described as a growth hormone-releasing hormone analogue. It is studied in relation to GHRH receptor signalling, growth hormone axis research, IGF-1 pathway models and metabolic research.
No. Tesamorelin is not full human growth hormone. It is studied as a GHRH analogue, meaning it relates to signalling upstream of growth hormone release rather than being growth hormone itself.
This research product is not approved or supplied for fat loss, visceral fat reduction, obesity treatment, HIV-associated lipodystrophy treatment or human use. It should be described only as a laboratory research product.
Tesamorelin is studied because the GHRH pathway is connected to growth hormone axis signalling, IGF-1 pathway models and metabolic research contexts, including visceral adipose tissue studies.
No. EGRIFTA and EGRIFTA SV are regulated prescription medicines in the United States with specific formulations, strengths, labels and approved indications. A research-use Tesamorelin 5mg vial is not equivalent to those regulated medicines.
The active research compound is the same product type, but the total vial content is different. The 5mg vial allows different concentration planning for qualified research settings. It should be treated as a strength variant, not a separate therapeutic claim.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Tesamorelin compound profile | Useful background on tesamorelin identity, molecular formula and molecular weight. |
| DailyMed EGRIFTA SV prescribing information | Useful context showing that regulated tesamorelin medicine instructions are formulation-specific and not transferable to research vials. |
| EGRIFTA SV indication and limitations summary | Useful background on regulated medicine context and why research vials should not make treatment or fat loss claims. |
Tesamorelin 5mg for qualified laboratory research only. Not for human or veterinary use.
